TEQUIN SUMMARY
TEQUIN contains gatifloxacin, a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent for oral or intravenous administration.
TEQUIN (gatifloxacin) is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below (see DOSAGE AND ADMINISTRATION).
Acute bacterial exacerbation of chronic bronchitis due to
Streptococcus pneumoniae,
Haemophilus influenzae,
Haemophilus parainfluenzae,
Moraxella catarrhalis, or
Staphylococcus aureus.
Acute sinusitis due to
Streptococcus pneumoniae
or
Haemophilus influenzae.
Community-acquired pneumonia due to
Streptococcus pneumoniae,
Haemophilus influenzae,
Haemophilus parainfluenzae,
Moraxella catarrhalis,
Staphylococcus aureus,
Mycoplasma pneumoniae,
Chlamydia pneumoniae, or
Legionella pneumophila.
Uncomplicated skin and skin structure infections (i.e., simple abscesses, furuncles, folliculitis, wound infections, and cellulitis) due to
Staphylococcus aureus
(methicillin-susceptible strains only) or
Streptococcus pyogenes.
NOTE: An insufficient number of patients with the diagnosis of impetiginous lesions were available for evaluation.
Uncomplicated urinary tract infections (cystitis) due to
Escherichia coli,
Klebsiella pneumoniae, or
Proteus mirabilis.
Complicated urinary tract infections due to
Escherichia coli,
Klebsiella pneumoniae, or
Proteus mirabilis.
Pyelonephritis due to
Escherichia coli.
Uncomplicated urethral and cervical gonorrhea due to
Neisseria gonorrhoeae. Acute, uncomplicated rectal infections in women due to
Neisseria gonorrhoeae
(see WARNINGS).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEQUIN and other antibacterial drugs, TEQUIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Tequin (Gatifloxacin)
Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. [2011.09] AIM: To compare the aqueous humour penetration of moxifloxacin 0.5% and gatifloxacin 0.3% eye drops administered in two different dosing regimens during phacoemulsification surgery... CONCLUSION: Moxifloxacin, given in the same dosage, penetrated the aqueous humour better then gatifloxacin during cataract surgery. The penetration of both antibiotics increased significantly when the dosage of the agent was doubled.
A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. [2011.08] CONCLUSIONS: We conclude that in Vietnam, where nalidixic acid resistant Shigellae are highly prevalent, ciprofloxacin and gatifloxacin are similarly effective for the treatment of acute shigellosis.
Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. [2011.06] PURPOSE: To determine the concentrations of besifloxacin, moxifloxacin, and gatifloxacin in human aqueous humor after topical instillation of commercially available besifloxacin ophthalmic suspension 0.6%, moxifloxacin ophthalmic solution 0.5%, and gatifloxacin ophthalmic solution 0.3%, and to assess these concentrations relative to the minimum inhibitory concentration for 90% of strains (MIC(90)) for each drug against bacterial pathogens identified in recent cases of postoperative endophthalmitis. SETTING: Six clinical sites, United States. DESIGN: Randomized open-label controlled clinical trial... CONCLUSIONS: Based on the aqueous humor drug concentrations measured in this study, it is unlikely that any of the fluoroquinolones tested would be therapeutically effective in the aqueous humor against the most frequently identified drug-resistant staphylococcal isolates from recent cases of postoperative endophthalmitis. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. [2011.06] BACKGROUND: We aimed to investigate whether gatifloxacin, a new generation and affordable fluoroquinolone, is better than chloramphenicol for the treatment of uncomplicated enteric fever in children and adults... INTERPRETATION: Although no more efficacious than chloramphenicol, gatifloxacin should be the preferred treatment for enteric fever in developing countries because of its shorter treatment duration and fewer adverse events. FUNDING: Wellcome Trust. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. [2009.08] PURPOSE: We sought to assess the efficacy of 3-day topical gatifloxacin use in combination with povidone-iodine (PVI) versus PVI alone in eliminating conjunctival bacterial flora in patients scheduled to undergo intravitreal (IVT) injection. DESIGN: Prospective, randomized single-blind clinical trial. PARTICIPANTS: We included 129 patients scheduled to undergo 273 IVT injections at California Vitreoretinal Center at Stanford University... CONCLUSIONS: Although 3-day topical gatifloxacin use is effective in reducing the frequency of conjunctival bacterial growth relative to untreated eyes, antibiotic use confers no additional benefit in combination with PVI than eyes receiving PVI alone. This supports that topical PVI is an effective preinjection monotherapy for infection prophylaxis in the setting of IVT injections.
Clinical Trials Related to Tequin (Gatifloxacin)
One Hour Preoperative Gatifloxacin [Completed]
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects [Completed]
This study is being conducted to assess the concentration of besifloxacin, moxifloxacin, or
gatifloxacin in aqueous humor samples collected following topical instillation of the
associated formulation in subjects undergoing cataract surgery.
Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation [Completed]
The purpose of the study is to evaluate the safety and tolerance of the 0. 3% gatifloxacin
and 1. 0% prednisolone acetate association in eye drops in the prevention of infection and
inflammation after refractive surgery (Lasik) and also demonstrate the non-inferiority of
the efficacy of this association compared to the administration of 0. 3% gatifloxacin and
1. 0% prednisolone acetate as isolated eye drops formulations. The study treatment is
randomized, double-masked, with 2 parallel arms. Each patient's participation lasts 29 days,
with 15 days of study treatment administration after the ocular surgery is performed.
Candidates for the study are patients with indication for ocular refractive surgery (Lasik)
for correction of visual acuity.
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation [Completed]
The purpose of this study is to assess the concentration of besifloxacin compared to
gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the
drug instilled topically into the study eye. Conjunctival biopsies will be performed at
specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic
suspension four times a day for 5 days.
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis [Completed]
This study will evaluate the ability of 4 antibiotics to kill the bacteria that cause
tuberculosis (TB). The antibiotics to be studied are linezolid, gatifloxacin, levofloxacin,
and moxifloxacin. All are approved by the Brazilian health authorities to treat infections
caused by germs other than TB. Seventy human immunodeficiency virus (HIV)-negative adults,
aged 18-65 years, who have been newly diagnosed with pulmonary (lung) TB, will participate
in this study. Study volunteers will be given one of the 4 study drugs or a comparison
antibiotic, Isoniazid, which has been used around the world as a standard of care treatment
for TB. Volunteers will stay in the hospital for 10 days and be given a study antibiotic 7
of those days. Blood and saliva samples will be taken. Six weeks later, volunteers will
return for a final health check. All volunteers will receive 6 months of standard
tuberculosis treatment.
Reports of Suspected Tequin (Gatifloxacin) Side Effects
Drug Hypersensitivity (4),
Tendon Rupture (2),
Rotator Cuff Syndrome (2),
Vomiting (2),
Nausea (2),
Arthralgia (1)
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Tequin has an overall score of 1. The effectiveness score is 2 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| Tequin review by 52 year old female patient | | Rating |
Overall rating: | | |
Effectiveness: | | Ineffective |
Side effects: | | No Side Effects | | Treatment Info |
Condition / reason: | | UTI |
Dosage & duration: | | 400 mg taken once a day for the period of 5 days |
Other conditions: | | hypothyroidism |
Other drugs taken: | | synthroid, pyridium | | Reported Results |
Benefits: | | pain relief, frequencey, urgency relief |
Side effects: | | none |
Comments: | | Tequin and pyridium per MD order. drink lots of water, void completely, wipe front to back, void before and after sexual intercourse, avoid chemicals around urethra like bubble baths, maintain cleanliness around urethra, drink cranberry juice and/or take vitamin C supplements to maintain acidic urine to inhibit bacteria from attaching to wall of bladder. |
|
|
Page last updated: 2011-12-09
|